 | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
This article should not be speedily deleted for lack of asserted importance because... I am currently working on it -- Oitio ( talk) 22:16, 10 April 2018 (UTC)
- This article doesn't tell us what is important about this company. Google doesn't either. The only results are self-published info and press releases. They have a drug in phase I trials, but this is statistically unlikely to become a pharmaceutical product.
Natureium (
talk) 22:22, 10 April 2018 (UTC)
- There are publications in scientific journals, we can add references. Shall we add more information about these orphan (rare) but debilitating and life-shortening (though not affecting cognition), neurodegeneration disorders to this article? The drug is single but it represents a fundamentally novel approach (heavy isotope nutrient) to otherwise incurable conditions. And it is not a recent development (WP is not news) - it has been in development over many years and now got to the stage of FDA approval and clinical trials with published results. Oitio ( talk) 23:28, 10 April 2018 (UTC)
Retrotope went through bankruptcy and was bought by a company named BioJiva (which I think was created for that purpose). See last paragraph of https://www.globenewswire.com/news-release/2022/09/15/2516727/0/en/BioJiva-Reports-Results-of-Pilot-Phase-2-Clinical-Trial-of-RT001-in-Patients-with-Amyotrophic-Lateral-Sclerosis-ALS.html and other pages found by Googling "BioJiva" together with "Retrotope" or "RT001".
I think this BioJiva is distinct from the Indian company Biojiva (with lower-case j): https://www.thecompanycheck.com/company/biojiva-healthcare-private-limited/U51909JH2019PTC012709
I'm not a Wikipedian; hope someone will incorporate this information, and likewise modify the page about RT001. 2600:1700:B8B8:40:E94E:1E42:36EB:1694 ( talk) 20:04, 22 October 2022 (UTC)
|
| This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
This article should not be speedily deleted for lack of asserted importance because... I am currently working on it -- Oitio ( talk) 22:16, 10 April 2018 (UTC)
- This article doesn't tell us what is important about this company. Google doesn't either. The only results are self-published info and press releases. They have a drug in phase I trials, but this is statistically unlikely to become a pharmaceutical product.
Natureium (
talk) 22:22, 10 April 2018 (UTC)
- There are publications in scientific journals, we can add references. Shall we add more information about these orphan (rare) but debilitating and life-shortening (though not affecting cognition), neurodegeneration disorders to this article? The drug is single but it represents a fundamentally novel approach (heavy isotope nutrient) to otherwise incurable conditions. And it is not a recent development (WP is not news) - it has been in development over many years and now got to the stage of FDA approval and clinical trials with published results. Oitio ( talk) 23:28, 10 April 2018 (UTC)
Retrotope went through bankruptcy and was bought by a company named BioJiva (which I think was created for that purpose). See last paragraph of https://www.globenewswire.com/news-release/2022/09/15/2516727/0/en/BioJiva-Reports-Results-of-Pilot-Phase-2-Clinical-Trial-of-RT001-in-Patients-with-Amyotrophic-Lateral-Sclerosis-ALS.html and other pages found by Googling "BioJiva" together with "Retrotope" or "RT001".
I think this BioJiva is distinct from the Indian company Biojiva (with lower-case j): https://www.thecompanycheck.com/company/biojiva-healthcare-private-limited/U51909JH2019PTC012709
I'm not a Wikipedian; hope someone will incorporate this information, and likewise modify the page about RT001. 2600:1700:B8B8:40:E94E:1E42:36EB:1694 ( talk) 20:04, 22 October 2022 (UTC)